Company: MYSEW
Filing Date: 2025-02-10
Form Type: 424B5
Source: 0001213900-25-011767
Chunk: 17

Company: Myseum, Inc.
Filing Date: 2025-02-10
Form: 424B5
Chunk 17
---
 personnel; |

| ● | disputes                                                                                             
 and litigations related to intellectual properties, proprietary rights, and contractual obligations; |

| ● | changes                                                                                 
 in applicable laws, rules, regulations, or accounting practices and other dynamics; and |

| ● | other                                                       
 events or factors, many of which may be out of our control. |

In addition, if the market
for stocks in our industry or industries related to our industry, or the stock market in general, experiences a loss of investor confidence,
the trading price of our common stock could decline for reasons unrelated to our business, financial condition and results of operations.
If any of the foregoing occurs, it could cause our stock price to fall and may expose us to lawsuits that, even if unsuccessful, could
be costly to defend and a distraction to management.

If you purchase our common stock in
this offering, you may incur immediate and substantial dilution in the net tangible book value of your shares.

The offering price per share
in this offering may exceed the net tangible book value per share of our common stock outstanding prior to this offering. Assuming that
an aggregate of 1,941,747 shares of our common stock are sold at a price of $3.09 per share, the last reported sale price of our common
stock on The Nasdaq Capital Market on February 6, 2025, for aggregate gross proceeds of approximately $6,000,000, and after deducting
commissions and estimated offering expenses payable by us, you would experience immediate dilution of $0.73 per share, representing the
difference between our pro forma as adjusted net tangible book value per share as of September 30, 2024 after giving effect to this offering
and the assumed public offering price. The exercise of outstanding stock options and warrants will result in further dilution of your
investment.

This dilution would be due
to the substantially lower price paid by some of our investors who purchased shares prior to this offering as compared to the assumed
price offered to the public in this offering and the exercise of stock options granted to our employees, directors and consultants as
well as the exercise of outstanding warrants and conversion of outstanding preferred stock. As a result of the dilution to investors purchasing
shares in this offering, investors may receive significantly less than the purchase price paid in this offering, if anything, in the event
of our liquidation. Further, because we expect we will need to raise additional capital to fund our future activities, we may in the future